The desirability and feasibility of economic studies of drugs post-launch Michael DrummondAnne MasonAdrian Towse Editorial Pages: 5 - 6
The relationship between health care expenditure and health outcomes John NixonPhilippe Ulmann Original Papers Pages: 7 - 18
Pharmacoeconomic modelling in schizophrenia Karina HansenChristophe LançonMondher Toumi Original Papers Pages: 19 - 29
Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients Monica MeritoPatrizio Pezzottifor the ICONA Study Group Original Papers Pages: 30 - 36
Fixed budgets as a cost containment measure for pharmaceuticals David GranlundNiklas RudholmMagnus Wikström Original Papers Pages: 37 - 45
The Danish effect on Swedish alcohol costs Johan JarlUlf-G. GerdthamJuan Merlo Original Papers Pages: 46 - 54
Prospective casemix-based funding, analysis and financial impact of cost outliers in all-patient refined diagnosis related groups in three Belgian general hospitals Magali PirsonDimitri MartinsPol Leclercq Original Papers Pages: 55 - 65
Case-control analysis of the financial cost of medication errors in hospitalized patients Jaime PinillaCarles MurilloCarlos Humet Original Papers Pages: 66 - 71
Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care Steven J. EdwardsHelen E. CampbellJonathan M. Plumb Original Papers Pages: 72 - 78
Off-patent drugs in Italy Livio GarattiniSimone Ghislandi Pricing and Reimbursement Systems in Europe Pages: 79 - 83
